| Literature DB >> 26876722 |
Daniel Huber1, Robin Henriksson2, Stina Jakobsson3, Nikolai Stenfors4, Thomas Mooe5.
Abstract
BACKGROUND: Acute coronary syndrome (ACS) is a major cause of death from a non-communicable disease. Secondary prevention is effective for reducing morbidity and mortality, but evidence-based targets are seldom reached and new interventional methods are needed. The present study is a feasibility study of a telephone-based secondary preventive programme in an unselected ACS cohort.Entities:
Mesh:
Year: 2016 PMID: 26876722 PMCID: PMC4753651 DOI: 10.1186/s13063-016-1203-x
Source DB: PubMed Journal: Trials ISSN: 1745-6215 Impact factor: 2.279
Fig. 1Study flow chart
Patient characteristics
| Included | Excluded | Declined |
|
|
| ||||
|---|---|---|---|---|---|---|---|---|---|
|
| % or SD |
| % or SD |
| % or SD | i/e | i/d | d/e | |
| Subjects | 661 | 72.9 | 146 | 16.1 | 100 | 11 | |||
| Gender (male) | 453 | 68.5 | 80 | 54.8 | 47 | 53 | 0.002 | <0.001 | 0.230 |
| Mean age (years ± SD) | 69.2 ± 11.9 | 76.3 ± 12.1 | 77.3 ± 11.7 | <0.001 | <0.001 | 0.499 | |||
| Basic characteristics | |||||||||
| mRS >3 | 7 | 1.1 | 33 | 22.6 | 8 | 8.0 | <0.001 | <0.001 | 0.003 |
| eGFR | 78.4 ± 21.3 | 68.9 ± 22.9 | 70.4 ± 21.5 | <0.001 | 0.001 | 0.597 | |||
| eGFR <60 | 128 | 19.4 | 52 | 35.6 | 29 | 29 | <0.001 | 0.026 | 0.278 |
| eGFR 60–90 | 308 | 46.6 | 66 | 45.2 | 50 | 50 | 0.76 | 0.525 | 0.459 |
| eGFR >90 | 225 | 34.0 | 28 | 19.2 | 21 | 21 | <0.001 | 0.009 | 0.725 |
| BMI (mean ± SD) | 27.3 ± 4.5 | 25.8 ± 5.2 | 26.4 ± 5 | 0.001 | 0.077 | 0.375 | |||
| BMI <18.5 | 5 ± 0.8 | 14 ± 10.1 | 3 ± 3.1 | <0.001 | 0.070 | 0.044 | |||
| BMI 18.5–25 | 206 ± 31.2 | 49 ± 35.3 | 34 ± 35.1 | 0.347 | 0.442 | 0.975 | |||
| BMI 25–30 | 295 ± 44.6 | 53 ± 38.1 | 39 ± 40.2 | 0.160 | 0.413 | 0.748 | |||
| BMI >30 | 155 ± 23.4 | 23 ± 16.5 | 21 ± 21.6 | 0.075 | 0.695 | 0.322 | |||
| Only basic education | 345 | 52.2 | 99 | 67.8 | 77 | 77.0 | <0.001 | <0.001 | 0.231 |
| Heredity (first line) | 178 | 27.3 | 28 | 21.5 | 20 | 21.5 | 0.173 | 0.237 | 0.995 |
| Previous morbidities | |||||||||
| Previous IHD | 156 | 23.6 | 51 | 34.9 | 34 | 34.0 | 0.005 | 0.025 | 0.880 |
| Current NSTEMI | 420 | 63.5 | 100 | 68.5 | 69 | 69.0 | 0.258 | 0.288 | 0.933 |
| Current STEMI | 182 | 27.5 | 42 | 28.8 | 25 | 25.0 | 0.763 | 0.596 | 0.514 |
| Previous stroke | 48 | 7.3 | 26 | 17.8 | 15 | 15.0 | <0.001 | 0.009 | 0.562 |
| Peripheral artery disease | 15 | 2.3 | 8 | 5.5 | 5 | 5.0 | 0.035 | 0.112 | 0.869 |
| Congestive heart failure CHF (Previous) | 23 | 3.5 | 20 | 13.7 | 10 | 10.0 | <0.001 | 0.003 | 0.384 |
| Smoking (current/previous) | 414 | 62.6 | 79 | 54.1 | 57 | 57.0 | 0.065 | 0.272 | 0.697 |
| Atrial fibrillation | 95 | 14.8 | 42 | 29.4 | 26 | 26.0 | <0.001 | 0.002 | 0.701 |
| Hyperlipidemia | 463 | 96.1 | 110 | 96.5 | 80 | 100 | 0.829 | 0.071 | 0.090 |
| Hypertension | 354 | 53.6 | 95 | 65.1 | 67 | 67.0 | 0.011 | 0.012 | 0.754 |
| Diabetes | 135 | 20.4 | 45 | 30.8 | 28 | 28.0 | 0.006 | 0.085 | 0.634 |
p values for comparison: i/e, included versus excluded; i/d, included versus declined; d/e, declined versus excluded. Hyperlipidemia: treatment initiated or untreated total cholesterol >4.5 mmol/L or untreated LDL cholesterol >2.5 mmol/L
BMI body mass index, eGFR estimated glomerular filtration rate, IHD ischemic heart disease, LDL low-density lipoprotein, mRS modified Rankin scale, NSTEMI non-ST-elevation myocardial infarction, SD standard deviation, STEMI ST-elevation myocardial infarction
Fig. 2a Multivariate association with decision to decline participation. b With exclusion. Age 65 years or under was used as a reference category
Fig. 3One-year survival Kaplan-Meier estimates and group comparison. Odds ratio (OR) for mortality. p/np participant/non-participant, i included, e excluded, d declined